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Background: Globalization of clinical trials has important consequences for trial planning and interpretation. This
study investigated heterogeneity in patient characteristics and outcomes among world regions in the global
idalopirdine Phase 3 clinical program.
Methods: Data were pooled from three 24-week randomized controlled trials in patients aged ≥ 50 years with
mild-to-moderate Alzheimer’s disease (AD) (n = 2506). Patients received idalopirdine (10, 30, or 60 mg/day) or
placebo, added to cholinesterase inhibitor treatment. Patients were categorized into the following regions: Eastern
Europe/Turkey (n = 759), Western Europe/Israel (n = 709), USA/Canada (n = 444), South America/Mexico (n = 361), Asia
(n = 134), and Australia/South Africa (n = 99). For each region, operational characteristics, baseline demographic and
clinical characteristics, adverse events, and mean change from baseline to week 24 in clinical rating scale scores
(placebo group only) were summarized using descriptive statistics.
Results: Completion rates were 0.86–0.90 in all regions. Heterogeneity among global regions was evident. Protocol
deviations were twice as common in South America/Mexico as in USA/Canada (2.64 vs 1.35 per patient screened).
Educational level ranged from 9.2 years in South America/Mexico to 13.4 years in USA/Canada. APOE ε4 carriage was
80.6% in Australia/South Africa, 63.1% in Western Europe/Israel, and < 60% in other regions. Screening Mini–Mental
State Examination scores were higher in Eastern Europe/Turkey (18.0) and USA/Canada (17.5) than in other regions
(16.9–17.1). Baseline AD Assessment Scale—Cognitive subscale (ADAS-Cog) scores ranged from 24.3 in USA/Canada to
27.2 in South America/Mexico. Baseline AD Cooperative Study—Activities of Daily Living, 23-item version (ADCS-ADL23)
scores ranged from 58.5 in USA/Canada to 53.5 in Eastern Europe/Turkey. In the placebo group, adverse events were
1.6–1.7 times more common in Western Europe/Israel, USA/Canada, and Australia/South Africa than in Eastern Europe/
Turkey. On the ADAS-Cog, Australia/South Africa and Western Europe/Israel showed the most worsening among patients
receiving placebo (1.56 and 1.40 points, respectively), whereas South America/Mexico showed an improvement (−0.71
points). All regions worsened on the ADCS-ADL23, from −3.21 points in Western Europe/Israel to −0.59 points in Eastern
Europe/Turkey.
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Conclusions: Regional heterogeneity—in terms of study conduct, patient characteristics, and outcomes—exists, and
should be accounted for, when planning and conducting multinational AD clinical trials.
Trial registration: ClinicalTrials.gov, NCT01955161. Registered on 27 September 2013.
ClinicalTrials.gov, NCT02006641. Registered on 5 December 2013.
ClinicalTrials.gov, NCT02006654. Registered on 5 December 2013.
Keywords: Alzheimer’s disease, Humans, Patient selection, Globalization, Clinical trial, Dementia, Disease progression,
Cognitive dysfunction, Cognitive decline, Activities of daily livingBackground
Alzheimer’s disease (AD) is a highly prevalent, age-related,
degenerative brain disease, associated with considerable
burden for patients, their family members, caregivers, and
society [1]. As the global elderly population increases, the
costs associated with AD are also expected to rise [1]. Cur-
rently, only two classes of drug are approved for the treat-
ment of AD: cholinesterase inhibitors (ChEIs) and an
N-methyl-D-aspartate (NMDA) receptor antagonist, mem-
antine [2, 3]. While these agents, and their combination,
can provide patients with a symptomatic benefit [2, 4],
there remains an urgent need for additional treatment op-
tions that can prevent AD, delay its onset, slow its progres-
sion, or improve its symptoms [5].
Increasingly, clinical trials of potential new drugs in AD
are conducted on an international basis, which allows for
faster recruitment of patients, has lower costs, and pro-
vides the opportunity to pursue registration and sales in
different regions [6, 7]. However, in a global trial, hetero-
geneity may emerge among geographic regions in terms
of clinical characteristics, demographics, comorbidities,
clinical measures, and side-effect profiles [6, 8]. This het-
erogeneity may arise due to differences among regions in
pharmacokinetics and pharmacogenetics, the culture of
diagnosis and care, the translation of study materials, the
experience of study sites, and the attitudes of patients and
investigators toward clinical studies [6, 8].
The extent to which these regional factors can impact
clinical study outcomes, and to which they should be
considered in the design of multinational studies, is un-
known. Using data from the multinational Phase 3 clin-
ical program of idalopirdine, the aim of this analysis was
to understand the effect of globalization on AD clinical
trial design and outcomes by comparing study conduct,
patient completion rates, patient characteristics, adverse
events, and disease progression across regions.Methods
Study design and patients
Data were pooled from three 24-week, randomized,
double-blind, placebo-controlled studies in mild-to-
moderate AD: STARSHINE (ClinicalTrials.gov NCT01
955161), STARBEAM (ClinicalTrials.gov NCT02006641), and STARBRIGHT (ClinicalTrials.gov NCT020
06654). In these studies, treatment with idalopirdine—
a selective serotonin 5-HT6 receptor antagonist—did
not reduce cognitive loss compared with placebo over
24 weeks [9]. For a full description of the designs and
outcomes of these studies, see Atri et al. [9].
Each of the three studies had a similar design, compris-
ing: a 2-week screening period during which patient eligi-
bility was monitored by qualified medical staff employed by
the sponsor; a 24-week, randomized, double-blind treat-
ment period with regular safety and efficacy assessments;
and a 4-week safety follow-up period (or enrollment into
an open-label extension study). Patients were enrolled from
34 countries. The studies included male and female outpa-
tients aged ≥ 50 years with a National Institute of Neuro-
logical and Communicative Disorders and Stroke–
Alzheimer’s Disease and Related Disorders Association
(NINCDS-ADRDA) criteria diagnosis of probable AD [10],
with a Mini–Mental State Examination (MMSE) score of
12–22 at screening [11], and who had received a thera-
peutic and stable dose of ChEI for at least 4 months prior
to screening (donepezil in STARSHINE and STARBEAM,
any ChEI in STARBRIGHT). Patients were excluded if they
were taking memantine, had an alternative cause of demen-
tia, had serious non-AD central nervous system or somatic
disorders, had clinically significant abnormalities as deter-
mined by laboratory testing, or were taking concomitant
medications that would interfere with the safety and effi-
cacy assessments. Eligible patients were randomized to
double-blind treatment with idalopirdine (fixed doses of 10,
30, or 60 mg/day, depending on the study) or placebo,
taken in addition to their standard ChEI treatment.Outcome measures
The primary outcome measure of each study was the
AD Assessment Scale—Cognitive subscale (ADAS-Cog),
an 11-item, objective measure of cognitive impairment
scored from 0 to 70, with a higher score indicating more
impairment [12]. Key secondary outcome measures in
each study were the AD Cooperative Study—Activities
of Daily Living, 23-item version (ADCS-ADL23) and the
AD Cooperative Study—Clinical Global Impression of
Change (ADCS-CGIC). The ADCS-ADL23 is an informant-
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where a higher score indicates less impairment [13, 14]. The
ADCS-CGIC is a clinician-rated measure of: global severity
at baseline scored from 1 (normal, not at all ill) to 7 (among
the most extremely ill patients); and global change at
follow-up scored from 1 (marked improvement) to 7
(marked worsening), where 4 indicates no change [15, 16].
Other secondary outcome measures included the Neuro-
psychiatric Inventory (NPI) and the MMSE. The NPI is an
informant-rated measure of behavioral disturbance (adminis-
tered by the clinician) scored from 0 to 144, where a higher
score indicates more disturbance [17]. The MMSE is an ob-
jective measure of cognitive impairment scored from 0 to 30,
where a higher score indicates less impairment [11]. External
quality oversight methods, including central review of scale
administration, were used to achieve consistent and accurate
ratings throughout the studies for the ADAS-Cog, ADCS-
ADL23, ADCS-CGIC, and MMSE.
Safety was assessed via the reporting of adverse events,
classified according to the Medical Dictionary for Regu-
latory Activities (MedDRA) version 19.0.
Data analysis
For the present post-hoc analysis, patients were categorized
into geographic regions according to shared culture, history,
geography, and linguistic features, based on the work of
Glickman et al. [7] and previous regional studies of AD
[18, 19], adjusted for the regions included in the idalo-
pirdine global development program. The resulting six
geographic regions were: Eastern Europe/Turkey (com-
prising Bulgaria, Croatia, Czech Republic, Estonia,
Hungary, Lithuania, Poland, Romania, Serbia, Slovakia,
Turkey, and Ukraine); Western Europe/Israel (compris-
ing Belgium, Denmark, Finland, France, Germany,
Israel, Italy, Portugal, Spain, Switzerland, and United
Kingdom); USA/Canada (comprising Canada and USA);
South America/Mexico (comprising Argentina, Brazil,
Chile, and Mexico); Asia (comprising South Korea,
Singapore, and Taiwan); and Australia/South Africa
(comprising Australia and South Africa).
For each region, operational characteristics of the clin-
ical program were summarized using descriptive statis-
tics, including the number of sites that screened at least
one patient and that randomized at least one patient, the
number of patients screened and number of patients
randomized per month, and the randomization, comple-
tion, and protocol deviation rates.
Baseline demographic and clinical characteristics
were summarized descriptively by region for the
all-patients-treated set (APTS), defined as all random-
ized patients who took at least one dose of
double-blind medication. Statistical comparisons of
baseline variables across all regions were calculated
using Kruskal–Wallis tests for the continuousvariables, and chi-squared tests for the categorical
variables.
The incidences of adverse events, serious adverse
events, and deaths were summarized descriptively, per
patient in the APTS, by treatment group and by region.
Mean change from baseline to week 24 in the clinical
rating scale scores was summarized descriptively using ob-
served cases, by region, in the subpopulation of patients
who were randomized to placebo and completed their re-
spective study. For the ADCS-CGIC, which is itself a
measure of change from baseline, the mean absolute value
at week 24 was summarized using observed cases. Clinical
outcomes were investigated in the placebo group rather
than the total population to make the results more
generalizable, and to prevent the bias that may occur due
to a drug’s specific mode of action in relation to the gen-
etic and environmental differences in patients across re-
gions. Statistical comparisons of equality of variances were
calculated using Levene tests, and pairwise comparisons
between specific regions were calculated using Tukey
tests. In case the assumption of equal variances was vio-
lated, sensitivity analyses based on Games–Howell
post-hoc tests were performed. To evaluate whether re-
gional differences in observed change from baseline to
week 24 in the clinical rating scale scores were driven by
regional differences in educational level, a linear regres-
sion analysis that adjusted for both region and years of
education was used as a sensitivity analysis.
Testing was done using a 0.05 significance level
(two-sided) with no overall correction for multiple com-
parisons (regions were corrected for in the Tukey and
Games–Howell tests). The statistical analyses were per-
formed using SAS version 9.4 (SAS Institute Inc.).
Results
Study conduct
Operational characteristics of the clinical program across
regions are presented in Table 1. Western Europe/Israel
and USA/Canada had the greatest number of sites (135
and 132, respectively), whereas Asia and Australia/South
Africa had the fewest sites (27 and 16, respectively). In
Asia and USA/Canada, approximately a third of sites
were ‘minimal recruiters’ (randomizing 0–1 patients),
whereas in Eastern Europe/Turkey only 3.6% of sites
were minimal recruiters. Overall, randomization rates
were highest in Eastern Europe/Turkey (0.69 patients
randomized per patient screened) and lowest in Asia
and USA/Canada (0.51 and 0.48 patients randomized
per patient screened, respectively). Completion rates
were high in all regions, in the range of 0.86–0.90 com-
pleters per patient randomized. Protocol deviation rates
were highest in South America/Mexico (2.64 protocol
deviations per patient screened) and lowest in USA/
Canada (1.35 protocol deviations per patient screened).
Table 1 Operational characteristics of the clinical program by region
Eastern
Europe
/Turkey
Western
Europe
/Israel
USA
/Canada
South America
/Mexico
Asia Australia
/South Africa
Sites that screened at least 1 patient 83 135 132 45 27 16
Randomized 0 patients 1 6 19 1 5 2
Randomized 1 patient only 2 14 23 2 4 2
Randomized 0–1 patients (%) 3 (3.6) 20 (14.8) 42 (31.8) 3 (6.7) 9 (33.3) 4 (25.0)
Patients screened per montha 1.23 1.78 1.41 2.03 2.07 1.98
Patients randomized per monthb 0.84 1.22 0.58 1.30 0.92 0.98
Randomization ratec 0.69 0.64 0.48 0.66 0.51 0.54
Completion rated 0.89 0.90 0.89 0.88 0.90 0.86
Protocol deviation ratee 1.79 2.33 1.35 2.64 1.47 1.44
aMean of values for each site (number of patients screened/duration of screening period in months). Screening period was defined as the time from first patient
screened to last patient screened at the site; sites that screened patients for a period of < 7 days were assigned a screening period of 7 days for this calculation
bMean of values for each site (number of patients randomized/duration of screening period in months). Screening period was defined as the time from first
patient screened to last patient screened at the site; sites that screened patients for a period of < 7 days were assigned a screening period of 7 days for
this calculation
cMean of values for each site (number of patients randomized/number of patients screened)
dTotal number of patients completed across all sites/total number of patients randomized across all sites
eMean of values for each site (number of protocol deviations throughout the study/number of patients screened)
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A total of 2506 patients received at least one dose of
randomized treatment, split across the regions as fol-
lows: Eastern Europe/Turkey, 759 (30.3% of the total);
Western Europe/Israel, 709 (28.3%); USA/Canada, 444
(17.7%); South America/Mexico, 361 (14.4%); Asia, 134
(5.3%); and Australia/South Africa, 99 (4.0%).
Baseline demographics by region are presented in
Table 2. In summary, regional differences were observed
for height, weight, body mass index (BMI), educational
level, marital status, relationship of caregiver, apolipo-
protein E (APOE) ε4 carriage, and MMSE score (all p <
0.001), but not for age or sex. Specifically, height was
lowest in Asia (1.57 m) and South America/Mexico
(1.59 m), and comparable in the other regions (1.63–
1.64 m). Weight and BMI were lowest in Asia (57.6 kg,
23.4 kg/m2), and highest in Australia/South Africa
(71.9 kg, 26.8 kg/m2) and USA/Canada (71.6 kg, 26.6 kg/
m2). Educational level was lowest in South America/
Mexico (9.2 years) and Asia (9.6 years), and highest in
USA/Canada (13.4 years). The proportion of married pa-
tients was lowest in Eastern Europe/Turkey (58.2%) and
highest in Asia (77.6%). Most commonly, caregivers were
a spouse or partner in Western Europe/Israel, USA/
Canada, Asia, and Australia/South Africa, and a child in
Eastern Europe/Turkey and South America/Mexico.
APOE ε4 carriage was most common in Australia/South
Africa (80.6%), followed by Western Europe/Israel
(63.1%), and was < 60% in the other regions, being low-
est in Asia (51.5%).
At screening, the MMSE score was higher (indicating
less cognitive impairment) in Eastern Europe/Turkey
(18.0) and USA/Canada (17.5) than in the other regions(range 16.9–17.1). A similar pattern was seen at baseline.
All regions showed a mean improvement in the MMSE
score from screening to baseline. The degree of im-
provement ranged from 0.5 points in Eastern Europe/
Turkey to 0.9 points in USA/Canada, South America/
Mexico, and Australia/South Africa. For complete com-
parisons, see Table 2.
Clinical characteristics
Clinical characteristics by region are presented in Table 2.
Overall, regional differences were observed for time
since AD diagnosis, prestudy treatment duration, previ-
ous treatment with a ChEI, and previous treatment with
memantine (all p < 0.0001). Median time since AD diag-
nosis varied from 1.3 years in Eastern Europe/Turkey to
2.2 years in Australia/South Africa. Median prestudy
treatment duration varied from 1.0 year in Eastern Eur-
ope/Turkey to 1.3 years in Australia/South Africa and
USA/Canada. Previous treatment with a ChEI other than
donepezil (among patients currently treated with done-
pezil as required by protocol) ranged from 2.4% in East-
ern Europe/Turkey to 7.8% in Western Europe/Israel.
Previous treatment with memantine ranged from 1.0%
in Australia/South Africa to 20.0% in USA/Canada.
Baseline clinical rating scale scores
Regional differences at baseline, also presented in
Table 2, were observed for the ADAS-Cog, ADCS-
CGIC, and ADCS-ADL23 (all p < 0.0001), but not for the
NPI. The baseline ADAS-Cog score was lowest (less
cognitive impairment) in USA/Canada (24.3) and highest
(more cognitive impairment) in South America/Mexico
(27.2). The baseline ADCS-CGIC (severity) scores were
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and Asia (3.7), and highest (more severely ill) in Eastern
Europe/Turkey and Western Europe/Israel (both 3.9).
The baseline ADCS-ADL23 score was highest (less func-
tional impairment) in USA/Canada (58.5), and lowest
(more functional impairment) in Eastern Europe/Turkey
(53.5). Although not statistically different across all
groups, the baseline NPI score was lower (less behavioral
disturbance) in Asia (7.2) than in the other regions
(10.1–11.7).
Adverse events
The incidence of adverse events by region is pre-
sented in Table 3. The lowest incidence of adverse
events was in Eastern Europe/Turkey, and the highest
incidences were generally in Western Europe/Israel,
USA/Canada, and Australia/South Africa. In the pla-
cebo group, for example, adverse events were 1.6–1.7
times more common in Western Europe/Israel, USA/
Canada, and Australia/South Africa than in Eastern
Europe/Turkey. The incidence of serious adverse
events, and of deaths, was low and comparable in all
regions.
Observed change from baseline to week 24 in the
placebo group
Mean changes in the clinical rating scale scores from
baseline to week 24 in the placebo group are presented
in Table 4 and Fig. 1. On the ADAS-Cog, all regions
showed worsening except for South America/Mexico,
which showed an improvement (−0.71). The largest
changes from baseline were seen in Australia/South Af-
rica (1.56) and Western Europe/Israel (1.40). Regional
differences were also observed on the global outcome
(ADCS-CGIC) at week 24: Western Europe/Israel (mean
score 4.51), Australia/South Africa (4.41), and USA/
Canada (4.39) showed the most worsening, whereas
South America/Mexico (3.98) and Eastern Europe/
Turkey (4.18) showed no change or the least worsening.
Comparison of variance across regions revealed a differ-
ence for ADCS-CGIC (p < 0.0001), thus violating the as-
sumptions of the Tukey test. A sensitivity analysis
assuming unequal variances across regions (Games–
Howell post-hoc test) confirmed the significant pairwise
differences, except for USA/Canada and South America/
Mexico (adjusted p = 0.075).
All regions showed worsening on the functioning out-
come (ADCS-ADL23); the most worsening was seen in
Western Europe/Israel (−3.21), and the least in Eastern
Europe/Turkey (−0.59). The behavioral outcome (NPI)
showed improvement in all regions (range −0.13 to −1.73)
except for Western Europe/Israel (0.45). The MMSE score
worsened in all regions (range −0.34 to −1.22) except for
Eastern Europe/Turkey (0.10).When adjustments were made for education as well as
region, years of education predicted a faster rate of de-
cline on the ADAS-Cog (0.16 points per added year of
education, p = 0.0024), and the adjusted difference be-
tween Western Europe/Israel and South America/
Mexico remained significant. Years of education was not
a significant predictor for rate of decline for the other
endpoints (all p > 0.2).
Discussion
This analysis demonstrated considerable heterogeneity
among geographic regions in the multinational idalopir-
dine Phase 3 clinical program in AD. Despite the uneven
distribution of patients across regions, with small pro-
portions of the total population in Asia and Australia/
South Africa, heterogeneity was evident with regard to
study conduct, baseline demographic and clinical char-
acteristics, the incidence of adverse events, and the pro-
gression of disease in the placebo group. Differences
were evident despite all global sites using identical study
protocols.
Considering baseline demographic and clinical charac-
teristics, there was a 14-kg difference between the re-
gions with the greatest mean weight (USA/Canada and
Australia/South Africa) and the region with the lowest
mean weight (Asia). BMI followed a similar regional pat-
tern. Weight and BMI are important considerations in
clinical trial design, since they can affect drug distribu-
tion and clearance [20] and may affect brain exposure of
the administered agent. Patients in USA/Canada had, on
average, around 4 years’ more education than patients in
South America/Mexico and Asia. A greater level of edu-
cation has been linked to faster cognitive decline in AD
[21, 22], which was observed in this analysis on the
ADAS-Cog. The increased rate of decline is thought to
arise as a consequence of ‘cognitive reserve’, referring to
the ability of some people to tolerate greater neuro-
pathology without developing clinical symptoms [23].
Cognitive reserve is enhanced by education and, there-
fore, patients with a higher level of education have a
greater degree of pathology before clinical symptoms of
the disease become manifest [23]. Since the speed of
disease progression increases with disease severity,
these same patients may deteriorate more rapidly upon
diagnosis [21, 22].
Other than Australia/South Africa (80.6%), all regions had
a lower proportion of APOE ε4 carriers than has been ob-
served in populations of biologically proven AD patients
(around 70% in the EXPEDITION3 trial) [24]. This could
imply that non-AD patients were recruited into the program,
particularly at sites outside Australia and South Africa. Alter-
natively, these differences could reflect racial differences in
the frequency of APOE ε4, which is higher in black popula-
tions than white populations [25, 26]. The relationship
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Asia
Australia/South Africa
Eastern Europe/Turkey
South America/Mexico
USA/Canada
Western Europe/Israel
MMSE
NPI ADCS-ADL23
ADCS-CGIC
ADAS-Cog
100%
50%
0%
Fig. 1 Normalized observed decline from baseline to week 24 across regions in placebo group. 100%, maximal decline on the scale observed
across regions; 0%, minimum decline/maximum improvement observed on the scale across regions. ADAS-Cog Alzheimer’s Disease Assessment
Scale—Cognitive subscale, ADCS-ADL23 Alzheimer’s Disease Cooperative Study—Activities of Daily Living, 23-item version, ADCS-CGIC Alzheimer’s
Disease Cooperative Study—Clinical Global Impression of Change, MMSE Mini–Mental State Examination, NPI Neuropsychiatric Inventory
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among races, being strongest and most well established in
European and Asian populations [27, 28].
Several differences in diagnosis and treatment history
were observed across regions, which may reflect differ-
ences in culture, societal awareness of AD, and standard
of care. The time since AD diagnosis was almost a year
longer in Australia/South Africa than in Eastern Europe/
Turkey; this could suggest that patients in Eastern Eur-
ope/Turkey present to the clinic later in the disease (al-
though MMSE scores at screening were not lower in
Eastern Europe/Turkey, indicating a discrepancy be-
tween the two approaches to severity), or that study in-
clusion criteria (such as the requirement for stable
donepezil/ChEI treatment) selected for patients with a
greater disease duration in some regions.
Considering patient treatment history prior to enroll-
ment, use of a ChEI other than donepezil (among those
currently treated with donepezil) was low in all regions
(< 10%), whereas prior memantine treatment varied from
around 20% in USA/Canada and South America/Mexico
to < 10% in all other regions. In the USA, memantine is
often initiated as early as ChEIs, despite memantine not
being approved for use in mild disease [29]. In the South
America/Mexico group, memantine use was mainly
driven by patients from Argentina, where reimburse-
ment policy has historically favored memantine such
that it has become the most prescribed anti-dementia
drug [30]. Of note, the idalopirdine study entry criteria
excluded patients currently receiving memantine, which
may have contributed to inclusion of more atypicalpatients in regions where memantine use is common.
The reasons why patients stopped memantine treatment
prior to the start of the study were not collected.
Baseline clinical rating scale scores were heteroge-
neous among regions despite the fact that patients were
monitored for eligibility during the 2-week screening
period, and despite standardization of clinical rating
scale usage. There were also differences in patient stabil-
ity during the screening period, as shown by variation in
the change in MMSE score from the screening visit to
the baseline visit. Overall, at baseline, patients were least
cognitively impaired in USA/Canada, and most impaired
in South America/Mexico. Patients in USA/Canada also
had the least impairment of functioning at baseline. The
greatest impairment in functioning was observed in
Eastern Europe/Turkey, which could reflect reporting
behaviors of the different informants in this region, with
a low proportion of married patients and with more pa-
tients being cared for by a child rather than by a spouse
or partner. The suitability of activity of daily living
(ADL) items to elderly patients differs across regions
and can potentially affect functional metrics [31, 32]. Fi-
nally, patients showed numerically less behavioral dis-
turbance in Asia than in other regions. Neuropsychiatric
symptoms are known to vary among cultures, being in-
fluenced by lack of recognition, misinterpretation of cer-
tain behaviors, and social stigma [33–36].
Based on analysis of the change in clinical rating scale
scores over the first 6 months in the placebo group, the
greatest decline (on ADAS-Cog, ADCS-CGIC, and
ADCS-ADL23) was observed in Western Europe/Israel
Cummings et al. Alzheimer's Research & Therapy          (2018) 10:116 Page 11 of 13and Australia/South Africa, and the least decline was ob-
served in Eastern Europe/Turkey and South America/
Mexico. The variations may reflect differences in stand-
ard of care or accuracy of diagnosis among regions, as
well as the proportion of APOE ε4 carriers. Such varia-
tions in placebo decline will influence the outcome of
clinical trials, since low rates of decline among patients
receiving placebo will make it more difficult to distin-
guish a treatment effect.
Overall, two regions stood out in their patterns of charac-
teristics at screening/baseline and their subsequent out-
comes/trajectories: Eastern Europe/Turkey and South
America/Mexico. Eastern Europe/Turkey had the most im-
paired functioning (ADCS-ADL23) at baseline as well as the
least worsening in functioning, which could reflect: the low
proportion who were married and differences between in-
formants, as already discussed; cultural differences in the
appreciation of the importance of different ADLs; and the
positive effect on quality of life and standard of care that
can be achieved from enrollment in a clinical trial. This lat-
ter point may also be reflected in the observation that East-
ern Europe/Turkey was the only region to show
improvement on the MMSE over 24 weeks in the placebo
group. With regard to South America/Mexico, a similar
pattern to that of Eastern Europe/Turkey was observed in
terms of baseline ADCS-ADL23, change in ADCS-ADL23,
and proportion of married patients. In addition, South
America/Mexico was the only region to show improvement
on the ADAS-Cog over 24 weeks (placebo group), despite
having the most cognitive impairment at baseline; this may
be linked to the lower level of education in this region and
differing approaches to diagnosis.
The studies involved in this analysis used a centralized
review of scale administration, which reduces adminis-
tration errors and deviations. Studies not using central-
ized rating may exhibit more variability.
The incidence of adverse events across treatment arms
tended to be higher in Western Europe/Israel, USA/
Canada, and Australia/South Africa than in other re-
gions. In the idalopirdine 60 mg/day group, for example,
patients in USA/Canada experienced on average one
more adverse event than patients in Eastern Europe/
Turkey and South America/Mexico. This may have been
influenced by differences in baseline medical status (i.e.,
comorbidities) across regions. Awareness of such varia-
tions in adverse event reporting is important for industry
sponsors of drug development programs, since reports
from Eastern Europe and South America may not reflect
the side-effect profile seen in other global regions.
Other large multinational AD clinical programs (e.g.,
semagacestat and solanezumab) have also shown heterogen-
eity among geographic regions [18, 19]. Compared with the
idalopirdine clinical program, the patterns of heterogeneity
were generally similar with regard to baseline demographicand clinical characteristics, with, for example, weight being
highest in USA/Canada and Australia/South Africa, and low-
est in Asia (and Japan, a separate region in [18]); patient
functioning being worst in Eastern Europe and best in USA/
Canada; patients showing less behavioral disturbance in Asia
(and Japan in [18]) than in other regions; and the incidence
of adverse events across treatment arms tending to be higher
in USA/Canada and Australia/South Africa than in other re-
gions. Completion rates were high and similar in all regions
in the idalopirdine clinical program, whereas significant dif-
ferences were found among regions in the semagacestat and
solanezumab programs. The idalopirdine studies were con-
siderably shorter (24 weeks) than the semagacestat/solanezu-
mab studies (76–80 weeks), so it is possible that differences
in completion rates would have emerged given a longer
study duration. Solanezumab requires monthly infusions,
which may also have influenced participant retention. Fur-
thermore, there may be differences between trials of a symp-
tomatic agent versus a potentially disease-modifying agent.
Heterogeneity may arise for many reasons, including
differences in culture and standard of care for patients
with AD. A heterogeneous patient population can be ad-
vantageous in a clinical program in order to show how
an investigative agent affects a real-world AD popula-
tion. However, it is possible that a heterogeneous patient
population may indicate that patients without AD or
with atypical AD are being included, making it more dif-
ficult to observe a treatment effect, and highlighting the
importance in future AD dementia trials of recruiting
patients with biomarker evidence of amyloid pathology
and neurodegeneration, if proposed research diagnostic
criteria are validated.
This analysis of a large clinical trial program is limited
by its post-hoc nature, since these studies were not de-
signed to assess regional differences. In addition, homo-
geneity was not tested within the defined geographic
regions, the population sizes were small in the Asia and
Australia/South Africa groups, and the analysis did not
control for multiple comparisons. These analyses are
intended to provide observations of potential importance
to those planning, conducting, and interpreting global
clinical trials.
Conclusions
These analyses—conducted on a large, global, clinical trial
program—demonstrated that regional heterogeneity exists in
multinational AD clinical trials, and that it should be
accounted for, whether by limiting or excluding certain
countries, increasing sample size to account for the variance,
or finding additional means of increasing homogeneity (e.g.,
biomarkers). Sponsors must be familiar with regional differ-
ences in order to appropriately plan and power studies of
global programs. Differences in training and vigilance may
also be required among regions.
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